Alkmaar

• Iberdomide combined with low-dose cyclophosphamide and dexamethasone: ICON study Recruiting
  2023-508902-66-00 4 2024-11-28 relapsed / refractory multiple myeloma
• Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study Recruiting
  2024-518878-14-01 6 2024-11-25 Inflammatory bowel disease
• A trial to test the effect of obicetrapib/ezetimibe on coronary plaque characteristics on coronary computerized tomography angiography in pe … Recruiting
  2023-508475-36-00 5 2024-10-29 Atherosclerotic Cardiovascular Disease
• DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting
  2023-506115-17-00 5 2024-10-14 Metastatic Colorectal Cancer
• Tranexamic acid to prevent OpeRation in Chronic subdural Hematoma (TORCH) Recruiting
  2024-514927-40-02 11 2024-10-01 Chronic Subdural Hematoma
• STOP-IMH Recruiting
  2024-517783-37-00 6 2024-09-20 ST elevation myocardial infarction (STEMI)
• CLEAR-PATH trial Recruiting
  2024-513363-15-01 11 2024-07-22 (Chronic) Peripheral (occlusive) arterial disease (PAD)
• INJECTABL-II trial: Dose finding, efficacy and immunological response of a novel immuno-adjuvant (IP-001) following microwave ablation or ir … Recruiting
  2023-504572-25-00 9 2024-06-25 Colorectal liver metastases
• PEPPER-trial Recruiting
  2023-507763-18-01 6 2024-05-21 Placenta previa, preterm birth
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa … Recruiting
  2022-500305-40-00 9 2024-04-10 Chronic Lymphocytic Leukemia
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol … Recruiting
  2023-506698-36-00 5 2024-02-02 low-volume metastatic castration-sensitive prostate cancer
• Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress Recruiting
  2023-509142-35-00 6 2024-01-29 Atrial fibrillation after stress (e.g., noncardiac surgery or acute me
• The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ … Recruiting
  2022-501620-26-00 6 2023-05-15 prosthetic joint infection
• WOEST-3 Recruiting
  2022-502140-13-00 6 2023-01-11 Atrial fibrillation Acute coronary syndrome Chronic coronary syndrome
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 … Recruiting
  2024-513797-22-00 5 2022-03-09 HER2 positive esophageal adenocarcinoma
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus … Recruiting
  2024-512526-28-00 5 2020-10-28 Locally recurrent rectal cancer
• Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients Recruiting
  2023-507868-39-00 6 2019-05-03 ANCA Vasculitis
• DRUP trial Recruiting
  2023-509152-33-00 4 2016-07-25 Advanced solid tumor
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled … Ended recruitment
  2024-516814-39-00 5 2025-05-20 Chronic rhinosinusitis with nasal polyps

Showing 25–48 of 91 trials